Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Syros Pharmaceuticals Inc...

    NASDAQ: SYRS · Real-Time Price · USD
    0.03
    0.00 (19.52%)
    At close: Jun 09, 2025, 3:26 PM

    Syros Pharmaceuticals Statistics

    Share Statistics

    Syros Pharmaceuticals has 26.83M shares outstanding. The number of shares has increased by 0.39% in one year.

    Shares Outstanding

    n/a
    		 26.83M

    Shares Change (YoY)

    n/a
    		 0.39%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 13.29%

    Shares Floating

    n/a
    		 26.68M

    Failed to Deliver (FTD) Shares

    n/a
    		 1,823

    FTD / Avg. Volume

    n/a
    		 0.01%

    Short Selling Information

    The latest short interest is 129.16K, so 0.48% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 129.16K

    Short % of Shares Out

    n/a
    		 0.48%

    Short % of Float

    n/a
    		 0.52%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -1.34 and the forward PE ratio is -0.04. Syros Pharmaceuticals's PEG ratio is -0.03.

    PE Ratio

    n/a
    		 -1.34

    Forward PE

    n/a
    		 -0.04

    PS Ratio

    n/a
    		 22.21

    Forward PS

    n/a
    		 0.4

    PB Ratio

    n/a
    		 13.24

    P/FCF Ratio

    n/a
    		 -2.01

    PEG Ratio

    n/a
    		 -0.03
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Syros Pharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 3.95, with a Debt / Equity ratio of 3.73.

    Current Ratio

    n/a
    		 3.95

    Quick Ratio

    n/a
    		 3.95

    Debt / Equity

    n/a
    		 3.73

    Debt / EBITDA

    n/a
    		 -0.39

    Debt / FCF

    n/a
    		 -0.56

    Interest Coverage

    n/a
    		 -25.16

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $146,117.65

    Profits Per Employee

    n/a
    		 $-2,420,205.88

    Employee Count

    n/a
    		 68

    Asset Turnover

    n/a
    		 0.06

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -99.42% in the last 52 weeks. The beta is 1.56, so Syros Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.56

    52-Week Price Change

    n/a
    		 -99.42%

    50-Day Moving Average

    n/a
    		 0.03

    200-Day Moving Average

    n/a
    		 0.69

    Relative Strength Index (RSI)

    n/a
    		 41.52

    Average Volume (20 Days)

    n/a
    		 20,465,601

    Income Statement

    In the last 12 months, Syros Pharmaceuticals had revenue of 9.94M and earned -164.57M in profits. Earnings per share was -5.81.

    Revenue

    n/a
    		 9.94M

    Gross Profit

    n/a
    		 7.68M

    Operating Income

    n/a
    		 -128.99M

    Net Income

    n/a
    		 -164.57M

    EBITDA

    n/a
    		 -157.19M

    EBIT

    n/a
    		 -159.45M

    Earnings Per Share (EPS)

    n/a
    		 -5.81
    Full Income Statement

    Balance Sheet

    The company has 139.53M in cash and 62.08M in debt, giving a net cash position of 77.45M.

    Cash & Cash Equivalents

    n/a
    		 139.53M

    Total Debt

    n/a
    		 62.08M

    Net Cash

    n/a
    		 77.45M

    Retained Earnings

    n/a
    		 -722.81M

    Total Assets

    n/a
    		 85M

    Working Capital

    n/a
    		 35.54M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -109.71M and capital expenditures -272K, giving a free cash flow of -109.98M.

    Operating Cash Flow

    n/a
    		 -109.71M

    Capital Expenditures

    n/a
    		 -272K

    Free Cash Flow

    n/a
    		 -109.98M

    FCF Per Share

    n/a
    		 -3.88
    Full Cash Flow Statement

    Margins

    Gross margin is 77.33%, with operating and profit margins of -1298.19% and -1656.34%.

    Gross Margin

    n/a
    		 77.33%

    Operating Margin

    n/a
    		 -1298.19%

    Pretax Margin

    n/a
    		 -1656.34%

    Profit Margin

    n/a
    		 -1656.34%

    EBITDA Margin

    n/a
    		 -1582.08%

    EBIT Margin

    n/a
    		 -1298.19%

    FCF Margin

    n/a
    		 -1106.87%

    Dividends & Yields

    SYRS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for SYRS is $3, which is 9900% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $3

    Price Target Difference

    n/a
    		 9900%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Sep 19, 2022. It was a backward split with a ratio of 1:10.

    Last Split Date

    n/a
    		 Sep 19, 2022

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:10

    Scores

    Altman Z-Score

    n/a
    		 -15.54

    Piotroski F-Score

    n/a
    		 0

    Add to Watchlist